NeuBase Therapeutics's market cap is currently ―. The company's EPS TTM is $-9.761; its P/E ratio is -0.04; NeuBase Therapeutics is scheduled to report earnings on February 8, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	-	$ -3.45M	$ -4.09M	-	$ -7.63M
EBITDA	-	-	$ -3.79M	-	$ -7.29M
Net Income Common Stockholders	-	$ -3.45M	$ -4.09M	-	$ -7.63M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 12.57M	$ 14.75M	$ 13.85M	$ 0.00	$ 23.15M
Total Assets	$ 18.62M	$ 22.33M	$ 21.46M	-	$ 32.69M
Total Debt	$ 5.34M	$ 5.47M	$ 5.62M	$ 0.00	$ 6.00M
Net Debt	$ -7.24M	$ -9.27M	$ -8.22M	$ 0.00	$ -17.16M
Total Liabilities	$ 9.48M	$ 11.09M	$ 7.01M	-	$ 9.50M
Stockholders Equity	$ 9.14M	$ 11.25M	$ 14.45M	$ 0.00	$ 23.19M
Cash Flow	-
Free Cash Flow	$ -2.00M	-	$ -3.45M	$ -5.62M	$ -6.67M
Operating Cash Flow	$ -2.00M	$ -3.64M	$ -3.45M	-	$ -6.64M
Investing Cash Flow	-	-	$ -4.95K	-	$ -28.81K
Financing Cash Flow	$ -174.50K	$ 4.55M	$ -88.42K	-	$ -27.30K

Currency in USD

NeuBase Therapeutics Earnings and Revenue History

Income Statement >

NeuBase Therapeutics Debt to Assets

Balance Sheet >

NeuBase Therapeutics Cash Flow

Cash Flow >

NeuBase Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing